{"transactions":[{"id":1241217,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T01:54:47.000Z","date":"2025-02-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":372000,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the \"Issuer\"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-005952","document":"form4-02282025_010242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925005952/form4-02282025_010242.xml","form_type":"4"}},{"id":1403917,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T20:31:08.000Z","date":"2024-09-18","kind":"purchase","planned":false,"acquired":true,"shares":32000,"price":17.21,"value":550720.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions ranging from $16.25 to $18.69."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":372000,"source":{"system":"sec-edgar","filing":"0001415889-24-023623","document":"form4-09182024_080904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924023623/form4-09182024_080904.xml","form_type":"4"}},{"id":1403916,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T20:31:08.000Z","date":"2024-09-17","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":15.33,"value":613200.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $13.04 to $17.22."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":340000,"source":{"system":"sec-edgar","filing":"0001415889-24-023623","document":"form4-09182024_080904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924023623/form4-09182024_080904.xml","form_type":"4"}},{"id":1403915,"issuer":{"id":82741,"kind":"organization","name":"Singular Genomics Systems, Inc.","symbol":"OMIC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T20:31:08.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":50416,"price":12.74,"value":642299.84,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $11.55 to $13.25. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001415889-24-023623","document":"form4-09182024_080904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924023623/form4-09182024_080904.xml","form_type":"4"}},{"id":1643605,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:25:51.000Z","date":"2023-06-01","kind":"other","planned":false,"acquired":false,"shares":4394800,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the \"Issuer\"), Adaptimmune Therapeutics plc (\"Parent\"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent (\"Parent ADS\"), representing six ordinary shares of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-003784","document":"form4-02142024_100232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924003784/form4-02142024_100232.xml","form_type":"4"}},{"id":1662208,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:00:12.000Z","date":"2024-01-26","kind":"other","planned":false,"acquired":false,"shares":3850513,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. (\"Parent\"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-002278","document":"form4-02022024_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924002278/form4-02022024_040201.xml","form_type":"4"}},{"id":1707666,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:29:00.000Z","date":"2023-12-18","kind":"sale","planned":false,"acquired":false,"shares":40132,"price":1.21,"value":48559.72,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were sold in multiple transactions ranging from $1.20 to $1.24."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3850513,"source":{"system":"sec-edgar","filing":"0001415889-23-016655","document":"form4-12182023_111254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588923016655/form4-12182023_111254.xml","form_type":"4"}},{"id":1707665,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:29:00.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":109435,"price":1.2,"value":131322.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions ranging from $1.20 to $1.22."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3890645,"source":{"system":"sec-edgar","filing":"0001415889-23-016655","document":"form4-12182023_111254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588923016655/form4-12182023_111254.xml","form_type":"4"}},{"id":1707664,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:29:00.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":24406,"price":1.21,"value":29531.26,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.22. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the ranges set forth in Footnotes 1, 3 and 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4000080,"source":{"system":"sec-edgar","filing":"0001415889-23-016655","document":"form4-12182023_111254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588923016655/form4-12182023_111254.xml","form_type":"4"}},{"id":1760676,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-13T20:57:52.000Z","date":"2023-10-13","kind":"purchase","planned":false,"acquired":true,"shares":84145,"price":0.99,"value":83303.55,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions ranging from $0.98 to $0.99."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4024486,"source":{"system":"sec-edgar","filing":"0001209191-23-052788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123052788/doc4.xml","form_type":"4"}},{"id":1760675,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-13T20:57:52.000Z","date":"2023-10-13","kind":"purchase","planned":false,"acquired":true,"shares":47486,"price":0.99,"value":47011.14,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $0.96 to $0.99."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3940341,"source":{"system":"sec-edgar","filing":"0001209191-23-052788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123052788/doc4.xml","form_type":"4"}},{"id":1760674,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-13T20:57:52.000Z","date":"2023-10-12","kind":"purchase","planned":false,"acquired":true,"shares":52514,"price":0.98,"value":51463.72,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $0.96 to $0.99."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3892855,"source":{"system":"sec-edgar","filing":"0001209191-23-052788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123052788/doc4.xml","form_type":"4"}},{"id":1760673,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-13T20:57:52.000Z","date":"2023-10-12","kind":"purchase","planned":false,"acquired":true,"shares":25188,"price":0.98,"value":24684.24,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $0.96 to $0.99."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3840341,"source":{"system":"sec-edgar","filing":"0001209191-23-052788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123052788/doc4.xml","form_type":"4"}},{"id":1760672,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-13T20:57:52.000Z","date":"2023-10-11","kind":"purchase","planned":false,"acquired":true,"shares":74812,"price":0.97,"value":72567.64,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.94 to $0.99. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1, 3 and 4 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3815153,"source":{"system":"sec-edgar","filing":"0001209191-23-052788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123052788/doc4.xml","form_type":"4"}},{"id":1872311,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-06-01","kind":"purchase","planned":false,"acquired":true,"shares":240341,"price":1.12,"value":269181.92,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"These shares were purchased in multiple transactions ranging from $1.10 to $1.12."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3740341,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872310,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-06-01","kind":"purchase","planned":false,"acquired":true,"shares":92984,"price":1.09,"value":101352.56,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"These shares were purchased in multiple transactions ranging from $1.04 to $1.11."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3500000,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872309,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-31","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.1,"value":5500.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"These shares were purchased in one transaction at $1.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3407016,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872308,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-31","kind":"purchase","planned":false,"acquired":true,"shares":161180,"price":1.08,"value":174074.4,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were purchased in multiple transactions ranging from $1.04 to $1.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3402016,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872307,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":5930,"price":1.06,"value":6285.8,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were purchased in multiple transactions ranging from $1.02 to $1.08."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3240836,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872306,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":2016,"price":1.08,"value":2177.28,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased in multiple transactions ranging from $1.075 to $1.08."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3234906,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872305,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":32890,"price":1.06,"value":34863.4,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions ranging from $1.05 to $1.08."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3232890,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872304,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":1,"value":200000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $0.96 to $1.03."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3200000,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1872303,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T22:46:33.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":347932,"price":1.05,"value":365328.6,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.96 to $1.15. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1, and Footnotes 3 through 10 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3000000,"source":{"system":"sec-edgar","filing":"0001209191-23-033446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/doc4.xml","form_type":"4"}},{"id":1875164,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T00:02:28.000Z","date":"2023-05-25","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.72,"value":86000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4394800,"source":{"system":"sec-edgar","filing":"0001209191-23-033041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123033041/doc4.xml","form_type":"4"}},{"id":1893771,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-15T21:12:15.000Z","date":"2023-05-12","kind":"purchase","planned":false,"acquired":true,"shares":6183,"price":1.95,"value":12056.85,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at $1.95."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4344800,"source":{"system":"sec-edgar","filing":"0001209191-23-029527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123029527/doc4.xml","form_type":"4"}},{"id":1893770,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-15T21:12:15.000Z","date":"2023-05-11","kind":"purchase","planned":false,"acquired":true,"shares":38765,"price":1.95,"value":75591.75,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.95. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4338617,"source":{"system":"sec-edgar","filing":"0001209191-23-029527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123029527/doc4.xml","form_type":"4"}},{"id":1898350,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T23:02:43.000Z","date":"2023-05-10","kind":"purchase","planned":false,"acquired":true,"shares":6774,"price":1.95,"value":13209.3,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $1.945 to $1.95."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4299852,"source":{"system":"sec-edgar","filing":"0001209191-23-028565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123028565/doc4.xml","form_type":"4"}},{"id":1898349,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T23:02:43.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":20141,"price":1.95,"value":39274.95,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at prices ranging from $1.92 to $1.95."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4293078,"source":{"system":"sec-edgar","filing":"0001209191-23-028565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123028565/doc4.xml","form_type":"4"}},{"id":1898348,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T23:02:43.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":57073,"price":1.95,"value":111292.35,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.94 to $1.95. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4272937,"source":{"system":"sec-edgar","filing":"0001209191-23-028565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123028565/doc4.xml","form_type":"4"}},{"id":1903098,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T22:52:56.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":71064,"price":1.94,"value":137864.16,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.95."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4215864,"source":{"system":"sec-edgar","filing":"0001209191-23-027833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123027833/doc4.xml","form_type":"4"}},{"id":1903097,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T22:52:56.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":95759,"price":1.9,"value":181942.1,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.88 to $1.94."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4144800,"source":{"system":"sec-edgar","filing":"0001209191-23-027833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123027833/doc4.xml","form_type":"4"}},{"id":1903096,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T22:52:56.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":104241,"price":1.86,"value":193888.26,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.90."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":4049041,"source":{"system":"sec-edgar","filing":"0001209191-23-027833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123027833/doc4.xml","form_type":"4"}},{"id":1903095,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T22:52:56.000Z","date":"2023-05-03","kind":"purchase","planned":false,"acquired":true,"shares":18513,"price":1.85,"value":34249.05,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.85. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3, 4 and 5 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":3944800,"source":{"system":"sec-edgar","filing":"0001209191-23-027833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123027833/doc4.xml","form_type":"4"}},{"id":1903094,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T20:37:26.000Z","date":"2023-05-03","kind":"other","planned":false,"acquired":true,"shares":10000,"price":9737.7,"value":97377000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-23-027688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123027688/doc4.xml","form_type":"4"}},{"id":1903093,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T20:37:26.000Z","date":"2023-05-03","kind":"other","planned":false,"acquired":false,"shares":5300087,"price":1.85,"value":9805160.95,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, (\"Concentra\"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra (\"Merger Sub\"), to which Concentra completed a tender offer (the \"Offer\") for shares of common stock of the Issuer, $0.001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 3, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the \"Cash Consideration\") plus one non-transferable contractual contingent value right per Share (each, a \"CVR,\" and each CVR together with the Cash Consideration, the \"Offer Price\"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-027688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123027688/doc4.xml","form_type":"4"}},{"id":1954686,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-15T00:39:33.000Z","date":"2023-03-14","kind":"purchase","acquired":true,"shares":20286,"price":1.018,"value":20651.148,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.02."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":5300087,"source":{"system":"sec-edgar","filing":"0001209191-23-018721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123018721/doc4.xml","form_type":"4"}},{"id":1954685,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-15T00:39:33.000Z","date":"2023-03-13","kind":"purchase","acquired":true,"shares":65701,"price":0.994,"value":65306.794,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":5279801,"source":{"system":"sec-edgar","filing":"0001209191-23-018721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919123018721/doc4.xml","form_type":"4"}},{"id":2175335,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series C-1(2) Convertible Preferred Stock","published_at":"2022-08-24T16:02:16.000Z","date":"2022-08-22","kind":"other","acquired":false,"shares":3519.315,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6067439},"source":{"system":"sec-edgar","filing":"0001209191-22-047314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122047314/doc4.xml","form_type":"4"}},{"id":2175334,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-24T16:02:16.000Z","date":"2022-08-22","kind":"other","acquired":false,"shares":9607934,"price":6.23,"value":59857428.82,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-047314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122047314/doc4.xml","form_type":"4"}},{"id":2491145,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":41290,"price":3.6644,"value":151303.076,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.75"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9607934,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491144,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":136255,"price":3.7586,"value":512128.043,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.89."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9649224,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491143,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":63745,"price":3.9461,"value":251544.1445,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.051."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9785479,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491142,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":6597,"price":3.9514,"value":26067.3858,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.95 to $3.96."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9849224,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2491141,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-01T19:07:25.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":193403,"price":4.1008,"value":793107.0224,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $4,380.25."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.74. The\nReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 and 4 through 7 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9855821,"source":{"system":"sec-edgar","filing":"0001209191-21-067347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121067347/doc4.xml","form_type":"4"}},{"id":2494411,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":160000,"price":9.6035,"value":1536560.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2494410,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":200000,"price":10.0722,"value":2014440.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":160000,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2494409,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":50889,"price":10.4279,"value":530665.4031,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":360000,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2494408,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":149111,"price":11.1892,"value":1668432.8012,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":410889,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2494407,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":75491,"price":11.7422,"value":886430.4202,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":560000,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2494406,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":124509,"price":12.4504,"value":1550186.8536,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":635491,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2494405,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Exit Filing"}}],"security":"Common Stock","published_at":"2021-11-26T18:02:06.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":161336,"price":13.5216,"value":2181520.8576,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":760000,"source":{"system":"sec-edgar","filing":"0001209191-21-066910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066910/doc4.xml","form_type":"4"}},{"id":2501192,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":38664,"price":6.5532,"value":253372.9248,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.71."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":921336,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501191,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":3719,"price":6.6627,"value":24778.5813,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $6.66 to $6.68."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":960000,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501190,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":196281,"price":7.1081,"value":1395184.9761,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $6.69 to $7.69."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":963719,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501189,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-22","kind":"sale","acquired":false,"shares":16667,"price":7.3589,"value":122650.7863,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.54."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1160000,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501188,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-19","kind":"sale","acquired":false,"shares":183333,"price":7.5205,"value":1378755.8265,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $7.20 to $8.09."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1176667,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501187,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-19","kind":"sale","acquired":false,"shares":30467,"price":8.0123,"value":244110.7441,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.15."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1360000,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501186,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":169533,"price":8.0947,"value":1372318.7751,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.34."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1390467,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501185,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":4023,"price":8.0015,"value":32190.0345,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.01."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1560000,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501184,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":152764,"price":8.3234,"value":1271515.8776,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $8.04 to $9.04."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1564023,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2501183,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T22:26:30.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":43213,"price":9.3845,"value":405532.3985,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $9.05 to $10.05. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 11 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1716787,"source":{"system":"sec-edgar","filing":"0001209191-21-066146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121066146/doc4.xml","form_type":"4"}},{"id":2503305,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-19","kind":"sale","acquired":false,"shares":365289,"price":1.9161,"value":699930.2529,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":12767435,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503304,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":381842,"price":1.8925,"value":722635.985,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":13132724,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503303,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":500000,"price":1.8812,"value":940600.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":13514566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503302,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":212423,"price":1.9708,"value":418643.2484,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":14014566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503301,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":287577,"price":2.1985,"value":632238.0345,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":14226989,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503300,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":500000,"price":2.0161,"value":1008050.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":14514566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503299,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":31151,"price":1.9941,"value":62118.2091,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15014566,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2503298,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T21:38:52.000Z","date":"2021-11-17","kind":"sale","acquired":false,"shares":468849,"price":2.6583,"value":1246341.2967,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15045717,"source":{"system":"sec-edgar","filing":"0001209191-21-065826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919121065826/doc4.xml","form_type":"4"}},{"id":2689880,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-01T18:42:29.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":43734,"price":4.5277,"value":198014.4318,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.35 to $4.65."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":10049224,"source":{"system":"sec-edgar","filing":"0001209191-21-036939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121036939/doc4.xml","form_type":"4"}},{"id":2689879,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-01T18:42:29.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":15358,"price":4.292,"value":65916.536,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.22 to $4.37."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":10005490,"source":{"system":"sec-edgar","filing":"0001209191-21-036939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121036939/doc4.xml","form_type":"4"}},{"id":2689878,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-01T18:42:29.000Z","date":"2021-05-27","kind":"purchase","acquired":true,"shares":184642,"price":4.4734,"value":825977.5228,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.40 to $4.50."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9990132,"source":{"system":"sec-edgar","filing":"0001209191-21-036939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121036939/doc4.xml","form_type":"4"}},{"id":2689877,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-01T18:42:29.000Z","date":"2021-05-27","kind":"purchase","acquired":true,"shares":1286,"price":4.4984,"value":5784.9424,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $4.49 to $4.50. The\nReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 5 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9805490,"source":{"system":"sec-edgar","filing":"0001209191-21-036939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121036939/doc4.xml","form_type":"4"}},{"id":2696028,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-26T16:56:55.000Z","date":"2021-05-26","kind":"purchase","acquired":true,"shares":166932,"price":4.2578,"value":710763.0696,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.77 to $4.50."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9804204,"source":{"system":"sec-edgar","filing":"0001209191-21-035962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121035962/doc4.xml","form_type":"4"}},{"id":2696027,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-26T16:56:55.000Z","date":"2021-05-25","kind":"purchase","acquired":true,"shares":31782,"price":3.8347,"value":121874.4354,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.89."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9637272,"source":{"system":"sec-edgar","filing":"0001209191-21-035962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121035962/doc4.xml","form_type":"4"}},{"id":2696026,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-26T16:56:55.000Z","date":"2021-05-25","kind":"purchase","acquired":true,"shares":95597,"price":3.7748,"value":360859.5556,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.67 to $3.90."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9605490,"source":{"system":"sec-edgar","filing":"0001209191-21-035962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121035962/doc4.xml","form_type":"4"}},{"id":2696025,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-26T16:56:55.000Z","date":"2021-05-24","kind":"purchase","acquired":true,"shares":104403,"price":3.6803,"value":384234.3609,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.425 to $3.80. The\nReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 5 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP."}],"balance_after":9509893,"source":{"system":"sec-edgar","filing":"0001209191-21-035962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919121035962/doc4.xml","form_type":"4"}},{"id":2933294,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-23T21:41:14.000Z","date":"2020-12-23","kind":"purchase","acquired":true,"shares":75784,"price":15.708,"value":1190415.072,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.53 to $15.79."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15514566,"source":{"system":"sec-edgar","filing":"0001209191-20-065024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120065024/doc4.xml","form_type":"4"}},{"id":2933293,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-23T21:41:14.000Z","date":"2020-12-23","kind":"purchase","acquired":true,"shares":63354,"price":15.4282,"value":977438.1828,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.15 to $15.60."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15438782,"source":{"system":"sec-edgar","filing":"0001209191-20-065024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120065024/doc4.xml","form_type":"4"}},{"id":2933292,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-23T21:41:14.000Z","date":"2020-12-22","kind":"purchase","acquired":true,"shares":36646,"price":15.1673,"value":555820.8758,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.69 to $15.25."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15375428,"source":{"system":"sec-edgar","filing":"0001209191-20-065024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120065024/doc4.xml","form_type":"4"}},{"id":2933291,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-23T21:41:14.000Z","date":"2020-12-22","kind":"purchase","acquired":true,"shares":37856,"price":14.5754,"value":551766.3424,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.05 to $14.75."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15338782,"source":{"system":"sec-edgar","filing":"0001209191-20-065024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120065024/doc4.xml","form_type":"4"}},{"id":2933290,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":4,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-23T21:41:14.000Z","date":"2020-12-21","kind":"purchase","acquired":true,"shares":62144,"price":14.5753,"value":905767.4432,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.22 to $14.75. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 6 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15300926,"source":{"system":"sec-edgar","filing":"0001209191-20-065024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120065024/doc4.xml","form_type":"4"}},{"id":2989937,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-06","kind":"purchase","acquired":true,"shares":2650,"price":23.87,"value":63255.5,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $23.85 to $23.87."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1760000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989936,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-06","kind":"purchase","acquired":true,"shares":107901,"price":23.48,"value":2533515.48,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $22.85 to $23.84."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1757350,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989935,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-06","kind":"purchase","acquired":true,"shares":29682,"price":22.33,"value":662799.06,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $21.85 to $22.84."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1649449,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989934,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-06","kind":"purchase","acquired":true,"shares":34044,"price":20.63,"value":702327.72,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.10 to $21.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1619767,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989933,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-05","kind":"purchase","acquired":true,"shares":8482,"price":20.94,"value":177613.08,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.86 to $21.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1585723,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989932,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-05","kind":"purchase","acquired":true,"shares":137241,"price":20.78,"value":2851867.98,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.18 to $21.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1577241,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989931,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-05","kind":"purchase","acquired":true,"shares":171626,"price":23.79,"value":4082982.54,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $23.09 to $24.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1440000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989930,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-05","kind":"purchase","acquired":true,"shares":71241,"price":15.32,"value":1091412.12,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.98 to $15.50."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1268374,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989929,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-05","kind":"purchase","acquired":true,"shares":77133,"price":14.22,"value":1096831.26,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.98 to $14.93."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1197133,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989928,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-05","kind":"purchase","acquired":true,"shares":160000,"price":15.31,"value":2449600.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.74 to $15.50."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":1120000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989927,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-04","kind":"purchase","acquired":true,"shares":160000,"price":16.84,"value":2694400.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $16.33 to $17.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":960000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989926,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-04","kind":"purchase","acquired":true,"shares":60146,"price":16.33,"value":982184.18,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $16.18 to $16.45."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989925,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-04","kind":"purchase","acquired":true,"shares":99854,"price":13.65,"value":1363007.1,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.18 to $14.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":739854,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989924,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-04","kind":"purchase","acquired":true,"shares":160000,"price":13.83,"value":2212800.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.33 to $14.00."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":640000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989923,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-04","kind":"purchase","acquired":true,"shares":88379,"price":13.11,"value":1158648.69,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $12.88 to $13.44."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":480000,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":2989922,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":3,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T21:47:54.000Z","date":"2020-11-04","kind":"purchase","acquired":true,"shares":68296,"price":10.63,"value":725986.48,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $10.11 to $11.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 17 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":391621,"source":{"system":"sec-edgar","filing":"0001209191-20-057304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120057304/doc4.xml","form_type":"4"}},{"id":3019990,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144952,"kind":"person","name":"Lemkey John G","position":4,"cik":"0001495904","reported_name":"Lemkey John G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":5,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-30T20:01:02.000Z","date":"2020-09-29","kind":"purchase","acquired":true,"shares":10882,"price":13.8484,"value":150698.2888,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.66 to $13.90."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15238782,"source":{"system":"sec-edgar","filing":"0001209191-20-052437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120052437/doc4.xml","form_type":"4"}},{"id":3019989,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":82742,"kind":"organization","name":"TANG CAPITAL PARTNERS LP","position":2,"cik":"0001191935","reported_name":"TANG CAPITAL PARTNERS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":3,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144952,"kind":"person","name":"Lemkey John G","position":4,"cik":"0001495904","reported_name":"Lemkey John G","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}},{"id":45594,"kind":"person","name":"Hearne Michael S","position":5,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-30T20:01:02.000Z","date":"2020-09-28","kind":"purchase","acquired":true,"shares":100000,"price":13.0571,"value":1305710.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $12.71 to $13.19. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are beneficially owned by Tang Capital Partners, LP (\"TCP\"). Kevin Tang is the sole manager of Tang Capital Management,\nLLC (\"TCM\"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of\ncommon stock that are held of record by Odonate Holdings, LLC (\"Holdings\"). Holdings has granted a proxy to TCP giving TCP the sole authority\nto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP."}],"balance_after":15227900,"source":{"system":"sec-edgar","filing":"0001209191-20-052437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000120919120052437/doc4.xml","form_type":"4"}}],"next_cursor":"2020-09-30T20:01:02.000000Z,3019989"}